Eli Lilly cuts cost of certain Zepbound doses by at least 50%

Published On Aug 27, 2024, 5:51 AM

Eli Lilly has significantly cut the prices of its Zepbound weight-loss drug, offering single-dose vials that cost at least 50% less than competing GLP-1 drugs. This move comes due to increased demand for the medication. The company expects this reduction to improve access for many people struggling with obesity, including those without insurance or coverage. Eli Lilly's earnings have been bolstered by the popularity of its medications in the GLP-1 class, with projections indicating a massive growth in the market over the next several years.

Read full article

Stock Forecasts

LLYView LLY chart on TradingView

Positive

Eli Lilly's decision to reduce the price of Zepbound could lead to increased sales, as more patients will be able to afford it compared to competitors. This strategic move is likely to enhance its market share in the rapidly growing GLP-1 drug market, projected to exceed $100 billion by 2030. Overall, this could contribute positively to Eli Lilly's revenue and earnings growth, making it an attractive investment opportunity.

Related News

Weight-loss drug competition heats up with growing pill market

Sep 17, 2024, 5:32 PM

GLP-1 pills are the next frontier for the weight-loss market.

LLY
NVO
PFE

Eli Lilly has been outperforming for many months: Alissa Coram

Investor's Business Daily executive editor Alissa Coram discusses whether the 'down' stock market is due for a bounce this week on 'Varney & Co.'

LLY

Why Big Pharma is betting on telehealth strategies

Sep 6, 2024, 4:52 PM

The telehealth world is entering a new phase of vertical integration in healthcare.

PFE
LLY